FindTrial
Sign In

An assessment of the Ceftolozane/Tazobactam and Imipenem/Relebactam activity in the hypervirulent Klebsiella pneumoniae

An assessment of the Ceftolozane/Tazobactam and Imipenem/Relebactam activity in the hypervirulent Klebsiella pneumoniae

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070223
Enrollment
Unknown
Registered
2023-04-06
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious disease

Interventions

hypervirulent Klebsiella pneumoniae:none

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 120 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old; 2. Kp was cultured positive and was associated with clinical infectious manifestations at the same time.

Exclusion criteria

Exclusion criteria: 1. Insufficient clinical data; 2. Bacterial strain not viable after storage; 3. Duplicate isolates from the same patient within 3 months.

Design outcomes

Primary

MeasureTime frame
30-day mortality;50% minimun inhibitory concentration, MIC50;90% minimun inhibitory concentration, MIC90;Microbial phenotype;Antibiotic sensitivity test;In vitro time killing test;Evaluate the impact of antibacterial drugs on toxicity;Molecular characteristics of pathogens;—

Secondary

MeasureTime frame
90 day all-cause mortality rate;Hospitalization days;Number of days staying in ICU;—

Countries

China

Contacts

Public ContactNing Shen

Peking University Third Hospital

shenningputh@163.com+86 136 9363 8871

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026